Pfizer, Inc. and Valneva SE announced the initiation of a Phase III clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety, and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
[Pfizer, Inc.]
